CINXE.COM

<div class="xbrl-content"> <h3>Quarterly report pursuant to Section 13 or 15(d)</h3> <div id="xbrl-menu-top"> <div class="navigation"> <ul class="xbrl-sf-menu"> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3082">Cover</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3082">Document And Entity Information</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3083">Financial Statements</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3083">CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3084">CONDENSED CONSOLIDATED BALANCE SHEETS</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3085">CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3086">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</a></li> </ul> </li> <li> <a class="menu-item current" href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3087">Notes to Financial Statements</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3087">Basis of Presentation and Summary of Significant Accounting Policies</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3088">Revenue Recognition</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3089">Selected Balance Sheet Data</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3090">Acquisitions</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3091">Fair Value Measurements</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3092">Debt and Other Financing Arrangements</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3093">Leases</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3094">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3095">Earnings Per Share</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3096">Share-based Compensation</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3097">Other Income / (Expense)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3098">Income Taxes</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3099">Segment Information</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3100">Subsequent Events</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3101">Pay vs Performance Disclosure</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3102">Insider Trading Arrangements</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3103">Accounting Policies</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3103">Basis of Presentation and Summary of Significant Accounting Policies (Policies)</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3104">Notes Tables</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3104">Basis of Presentation and Summary of Significant Accounting Policies (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3105">Revenue Recognition (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3106">Selected Balance Sheet Data (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3107">Acquisitions (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3108">Fair Value Measurements (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3109">Leases (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3110">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3111">Earnings Per Share (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3112">Other Income / (Expense) (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3113">Segment Information (Tables)</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3114">Notes Details</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3114">Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3115">Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3116">Revenue Recognition - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3117">Revenue Recognition - Disaggregation of Revenue (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3118">Selected Balance Sheet Data - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3119">Selected Balance Sheet Data - Inventories (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3120">Selected Balance Sheet Data - Property and Equipment (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3121">Selected Balance Sheet Data - Intangible Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3122">Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3123">Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3124">Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3125">Selected Balance Sheet Data - Other Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3126">Acquisitions - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3127">Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3128">Fair Value Measurements - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3129">Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3130">Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3131">Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3132">Debt and Other Financing Arrangements - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3133">Leases - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3134">Leases - Balance Sheet Classification (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3135">Leases - Cash Paid (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3136">Leases - Fair Value of the Lease Liability by Payment Date (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3137">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3138">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Consolidated Changes in Equity (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3139">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3140">Earnings Per Share - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3141">Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3142">Share-based Compensation (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3143">Other Income / (Expense) - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3144">Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3145">Income Taxes (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3146">Segment Information - Financial Information Relating to Reportable Segments (Details)</a></li> </ul> </li> </ul> </div> </div> <div class="spr-xbrl-document"> <h4>Segment Information</h4> <title></title> v3.24.3<table class="report" border="0" cellspacing="2" id="idm45979233362912"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;">Segment Information </div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Sep. 30, 2024</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );">Notes to Financial Statements</a></td> <td class="text"> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td> <td class="text"> Note 13. Segment Information: The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with the impact of partially-owned consolidated subsidiaries as well as acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Spatial Biology segments both include consumables, instruments, services, and royalty revenue. The following is financial information relating to the Company's reportable segments (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"> <tr style="height:1pt;"> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;">Quarter Ended </td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, </td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2024</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;">Net sales:</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"></td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Protein Sciences</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 204,535</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 204,655</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;">Diagnostics and Spatial Biology</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 83,192</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 72,797</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Other revenue(1)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 2,303</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> —</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;">Intersegment</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (572)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (517)</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Consolidated net sales</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 289,458</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 276,935</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"></td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Operating income:</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> </td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;">Protein Sciences</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 80,541</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 88,361</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Diagnostics and Spatial Biology</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,277</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 527</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;">Segment operating income</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 84,818</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 88,888</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Costs recognized on sale of acquired inventory</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (188)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (181)</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;">Amortization of intangibles</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> (19,741)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> (19,851)</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Acquisition related expenses and other</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (1,513)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 588</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;">Certain litigation charges</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> (292)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> —</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Stock based compensation, inclusive of employer taxes</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (10,637)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (11,494)</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;">Restructuring and restructuring-related costs</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> (11,022)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> (89)</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Corporate general, selling, and administrative expenses</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (1,586)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> (1,999)</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;">Impact of business held-for-sale(1)</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 148</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td> </tr> <tr> <td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;">Consolidated operating income</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,987</td> <td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td> <td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 55,862</td> </tr> </table> (1) Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023. </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div>No definition available.</div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td> Name:</td> <td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"> Namespace Prefix:</td> <td>us-gaap_</td> </tr> <tr> <td> Data Type:</td> <td>xbrli:stringItemType</td> </tr> <tr> <td> Balance Type:</td> <td>na</td> </tr> <tr> <td> Period Type:</td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;">Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 </div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td> Name:</td> <td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"> Namespace Prefix:</td> <td>us-gaap_</td> </tr> <tr> <td> Data Type:</td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td> Balance Type:</td> <td>na</td> </tr> <tr> <td> Period Type:</td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> <div style="clear:both;"></div> </div> </div> <link rel="stylesheet" href="//investors.bio-techne.com/stylesheets/xbrl.css" type="text/css">